For example, the Center for International Blood and Marrow Transplant Research (CIBMTR) only has data of patients with CBF‐AML receiving a HCT, while US cooperative groups may have too few patients with a long follow‐up to examine outcomes after HCT. This evidence concerns the gene CEBPZ and acute myeloid leukemia.